1. Home
  2. SRL vs CALC Comparison

SRL vs CALC Comparison

Compare SRL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$7.06

Market Cap

83.0M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$5.85

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRL
CALC
Founded
2017
2011
Country
China
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
88.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SRL
CALC
Price
$7.06
$5.85
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$16.00
AVG Volume (30 Days)
23.1K
104.8K
Earning Date
12-26-2025
11-12-2025
Dividend Yield
14.88%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,224,099.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.13
$1.42
52 Week High
$9.64
$7.20

Technical Indicators

Market Signals
Indicator
SRL
CALC
Relative Strength Index (RSI) 52.13 57.37
Support Level $6.58 $5.55
Resistance Level $9.64 $7.20
Average True Range (ATR) 0.61 0.80
MACD -0.06 -0.11
Stochastic Oscillator 23.95 50.48

Price Performance

Historical Comparison
SRL
CALC

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: